Leucine

Leucine

SCHEMBL891924

CC(C)C[C@H](N)C(=O)O.C[C@@H](O)[C@H](N)C(=O)O

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.75
SLC1A3 P43003 6/20 0.59
SLC1A2 P43004 6/20 0.59
SLC1A1 P43005 6/20 0.50
GRIK1 P39086 5/20 0.42
GRIK2 Q13002 2/20 0.42
GRIA2 P42262 2/20 0.40
GRIA4 P48058 2/20 0.40
GRIK3 Q13003 2/20 0.40
GRIK5 Q16478 2/20 0.40
RNPEP Q9H4A4 1/20 0.40
GRIA1 P42261 1/20 0.40
LAP3 P28838 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL891921 1.00 SLC7A5 (0.75) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL15323703 0.98 SLC7A5 (0.72) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL15323699 0.98 SLC7A5 (0.72) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL23292411 0.93 SLC7A5 (0.64) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL15323189 0.91 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL15323192 0.91 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL3495955 0.91 SLC7A5 (0.62) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL15323927 0.89 SLC7A5 (0.60) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL28932659 0.89 SLC7A5 (0.60) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL27464995 0.89 SLC7A5 (0.60) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117789993-B Establishment and application of gastric cancer prediction model based on tongue fur metabolite 浙江省肿瘤医院 2024-06-11 CN claimed
CN-117789993-A Establishment and application of gastric cancer prediction model based on tongue fur metabolite 浙江省肿瘤医院 2024-03-29 CN claimed
EP-2523662-A1 \"COMPOSITIONS COMPRISING AMINO ACIDS FOR PREVENTION AND/OR TREATMENT OF RENAL DISORDERS\ Professional Dietetics S.r.l. (IT) 2012-11-21 EP claimed
WO-2011086507-A1 \"COMPOSITIONS COMPRISING AMINO ACIDS FOR PREVENTION AND/OR TREATMENT OF RENAL DISORDERS\ PROFESSIONAL DIETETICS S.R.L. (IT) 2011-07-21 WO claimed
EP-2296642-A1 COMPOSITIONS COMPRISING AMINO ACIDS, WITH PRO-ANGIOGENIC ACTIVITY Professional Dietetics S.r.l. (IT) 2011-03-23 EP claimed
WO-2009147637-A1 COMPOSITIONS COMPRISING AMINO ACIDS, WITH PRO-ANGIOGENIC ACTIVITY PROFESSIONAL DIETETICS S.R.L. (IT) 2009-12-10 WO claimed
CN-117789993-B Establishment and application of gastric cancer prediction model based on tongue fur metabolite 浙江省肿瘤医院 2024-06-11 CN disclosed
CN-117789993-A Establishment and application of gastric cancer prediction model based on tongue fur metabolite 浙江省肿瘤医院 2024-03-29 CN disclosed
WO-2023248035-A1 COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL DISEASES PROFESSIONAL DIETETICS S.P.A. (IT) 2023-12-28 WO disclosed
US-10329575-B2 Regulatory sequence for plants CERES, INC. (US) 2019-06-25 US disclosed
US-20180223303-A1 SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY CERES INC (US) 2018-08-09 US disclosed
US-20170037426-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI (US) 2017-02-09 US disclosed
US-20160177419-A1 METHOD FOR SEPARATION OF RARE EARTH ION KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) 2016-06-23 US disclosed
US-20090265815-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded therapy ALEXANDROV NICKOLAI 2009-10-22 US disclosed
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby CERES, INC. (US) 2007-09-13 US disclosed
US-20060150283-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-07-06 US disclosed
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-03-02 US disclosed
WO-1996030398-A1 NOVEL AUTO ANTIGEN MURDOCH UNIVERSITY (AU) 1996-10-03 WO disclosed
US-4536397-A THERAPEUTIC DRUGS AND ANIMAL FEED ADDITIVES SANRAKU-OCEAN CO., LTD. (JP) 1985-08-20 US disclosed
US-4456592-A ANIMAL FEEDS SANRAKU-OCEAN CO. (JP) 1984-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037426-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 SLC7A5 3930/4885SLC1A3 4063/4885SLC1A2 4468/4885
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 SLC7A5 3930/4885SLC1A3 4063/4885SLC1A2 4468/4885
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 SLC7A5 3930/4885SLC1A3 4063/4885SLC1A2 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.